Anti-inflammatory effect and low ulcerogenic activity of etodolac, a cyclooxygenase-2 selective non-steroidal anti-inflammatory drug, on adjuvant-induced arthritis in rats

Pharmacology

Volumn 68, Issue 2, 2003, Pages 96-104

  Tachibana, Masaki ^a,b   Inoue, Naoki ^a   Yoshida, Eri ^a   Matsui, Masami ^a   Ukai, Yojiro ^a   Yano, Junichi ^a  

^a NIPPON SHINYAKU CO LTD   (Japan)

^b NONE   (Japan)

Author keywords

Adjuvant arthritis; Anti inflammatory; Cyclooxygenase 2; Etodolac; Non steroidal anti inflammatory drug; Safety index; Ulcerogenic activity

Indexed keywords

ACETIC ACID; CARRAGEENAN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; DOCEBENONE; ETODOLAC; INDOMETACIN; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; HYPERALGESIA; MALE; MOUSE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; RAT; SACCHAROMYCES CEREVISIAE; STOMACH MUCOSA; STOMACH ULCER; ULCEROGENESIS; WRITHING TEST;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; EDEMA; ETODOLAC; GASTRIC MUCOSA; INDOMETHACIN; MALE; MICE; PEPTIC ULCER; RATS; SPECIES SPECIFICITY; THIAZINES; THIAZOLES;

EID: 0037262689     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069536     Document Type: Article

References (39)

1. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692-2696.
2. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866-12872.
3. Vane J: Towards a better aspirin. Nature 1994;367:215-216.
4. Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, van de Putte LBA: Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 2000;43:4-13.
5. Ferdinandi ES, Cayen MN, Pace-Asciak C: Disposition of etodolac, other anti-inflammatory pyranoindole-1-acetic acids and furobufen in normal and adjuvant arthritic rats. J Pharmacol Exp Ther 1982;220:417-426.
6. Humber LG: Etodolac: The chemistry, pharmacology, metabolic disposition, and clinical profile of a novel anti-inflammatory pyranocarboxylic acid. Med Res Rev 1987;7:1-28.
7. Kawai S, Nishida S, Kato M, Furumaya Y, Okamoto R, Koshino T, Mizushima Y: Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. Eur J Pharmacol 1998;347:87-94.
8. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR: Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci USA 1999;96:7563-7568.
9. Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret JP, Ford-Hutchinson AW, Gordon R, Greig G, Gresser M, Guay J, Kargman S, Léger S, Mancini JA, O'Neill G, Ouellet M, Rodger IW, Thérien M, Wang Z, Webb JK, Wong E, Xu L, Young RN, Zamboni R, Prasit P, Chan CC: Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol 1997;121:105-117.
10. Ono K, Komatsubara Y, Akahori O, Mizushima T, Doi T, Kamei M, Yamamoto T, Ohzono K, Inoki R: Clinical evaluation of RAK-591 (etodolac) on low back pain, cervicobranchial syndrome and frozen shoulder: Double-blind study in comparison with diclofenac sodium. J Clin Ther Med 1991;7:799-834.
11. Homma M, Kuriyama K, Kashiwazaki S, Yoshizawa H, Nagaya I, Sugawara S, Akizuki M: Clinical evaluation of RAK-591 in rheumatoid arthritis: Double-blind study in comparison with indomethacin. J Clin Ther Med 1991;7:1287-1308.
12. Lanza F, Rack MF, Lynn M, Wolf J, Sanda M: An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa. J Rheumatol 1987;14:338-341.
13. Singh G, Terry R, Ramey D, Halpern J, Brown WB: Comparative GI toxicity of NSAIDs. XIX ILAR Congress of Rheumatology 1997, pp 159.
14. Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA: Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology 1989;96:647-655.
15. Neustadt DH: Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. J Rheumatol Suppl 1997;47:17-22.
16. Schleyerbach R, Wedde H: Alterations in the gastro-intestinal functions during the development of adjuvant disease in rats. Agent Action 1984;15:392-397.
17. McCafferty DM, Granger DN, Wallace JL: In-domethacin-induced gastric injury and leukocyte adherence in arthritic versus healthy rats. Gastroenterology 1995;109:1173-1180.
18. Kato S, Tanaka A, Kunikata T, Nishijima M, Takeuchi K: Changes in gastric mucosal ulcerogenic responses in rats with adjuvant arthritis: Role of nitric oxide. Aliment Pharmacol Ther 1999;13:833-840.
19. Kato S, Suzuki K, Ukawa H, Komoike Y, Takeuchi K: Low gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in rats with cirrhosis and arthritis. Dig Dis Sci 2001;46:1690-1699.
20. Wakitani K, Nanayama T, Masaki M, Matsushita M: Profile of JTE-522 as a human cy-clooxygenase-2 inhibitor. Jpn J Pharmacol 1998;78:365-371.
21. Takahashi Y, Taketani Y, Endo T, Yamamoto S, Kumegawa M: Studies on the induction of cyclooxygenase isozymes by various prostaglandins in mouse osteoblastic cell line with reference to signal transduction pathways. Biochem Biophys Acta 1994;1212:217-224.
22. Ohki S, Ogino N, Yamamoto S, Hayaishi O: Prostaglandin hydroperoxidase, an integral part of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem 1979;254:829-836.
23. Inoue K, Fujisawa H, Sasaki Y, Nishimura T, Nishimura I, Inoue Y, Yokota M, Masuda T, Ueda F, Shibata Y, Kimura K, Inoue K, Komiya Y, Nishioka J: Pharmacological properties of the new non-steroidal anti-inflammatory agent etodolac. Arzneimittelforsch 1991;41:228-235.
24. Inoue K, Fujisawa H, Motonaga A, Inoue Y, Kyoi T, Ueda F, Kimura K: Anti-inflammatory effects of etodolac: Comparison with other non-steroidal anti-inflammatory drugs. Biol Pharm Bull 1994;17:1577-1583.
25. Chan CC, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D, Hill RG, Li C, Mancini J, Penneton M, Prasit P, Rasori R, Riendeau D, Roy P, Tagari P, Vickers P, Wong E, Rodger IW: Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 1995;274:1531-1537.
26. Hawkey CJ, Jackson L, Harper SE, Simon TJ, Mortensen E, Lines CR: Review article: The gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans. Aliment Pharmacol Ther 2000;15:1-9.
27. Churchill L, Graham AG, Shin C-K, Pauletti D, Farina PR, Grob PM: Selective inhibition of human cyclooxygenase-2 by meloxicam. Inflammopharmacol 1996;4:125-135.
28. Ochi T, Motoyama Y, Goto T: The analgesic effect profile of FR122047, a selective cyclooxygenase-1 inhibitor, in chemical nociceptive models. Eur J Pharmacol 2000;391:49-54.
29. Goto K, Ochi H, Yasunaga Y, Matsuyuki H, Imayoshi T, Kusuhara H, Okumoto T: Analgesic effect of mofezolac, a non-steroidal anti-inflammatory drug, against phenylquinone-induced acute pain in mice. Prostaglandins Other Lipid Mediat 1998;56:245-254.
30. Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC, Gregory SA: Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 1996;97:2672-2679.
31. Taniguchi Y, Yokoyama K, Inui K, Deguchi Y, Furukawa K, Noda K: Inhibition of brain cyclooxygenase-2 activity and the antipyretic action of nimesulide. Eur J Pharmacol 1997;330:221-229.
32. Nantel F, Denis D, Gordon R, Northey A, Cirino M, Metters KM, Chan CC: Distribution and regulation of cyclooxygenase-2 in carrageenan-induced inflammation. Br J Pharmacol 1999;128:853-859.
33. 2 production following its intracellular conversion into cyclooxygenase inhibitors. Eur J Pharmacol 1997;329:181-187.
34. Whittle BJR, Higgs GA, Eakins KE, Moncada S, Vane JR: Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature 1980;284:271-273.
35. Dvornik DM: Tissue selective inhibition of prostaglandin biosynthesis by etodolac. J Rheumatol 1997;24:40-47.
36. Villegas I, Martin MJ, La Casa C, Motilva V, Alarcon de la Lastra C: Effects of meloxicam on oxygen radical generation in rat gastric mucosa. Inflamm Res 2000;49:361-366.
37. Wallace JL, McKnight W, Reuter BK, Vergnolle N: NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000;119:706-714.
38. Kato S, Tanaka A, Kunikata T, Mizoguchi H, Takeuchi K: The roles of nitrix oxide and prostaglandins in alterations of ulcerogenic and healing responses in adjuvant-induced arthritic rat stomachs. Aliment Pharmacol Ther 2000;14(suppl 1):18-25.
39. Kato S, Takeuchi K: Alteration of gastric ulcerogenic and healing responses in rats with adjuvant-induced arthritis. Jpn J Pharmacol 2002;89:1-6.